| [1] |
Zang L, Kondengaden SM, Che F, et al. Potential epigenetic-based therapeutic targets for glioma[J]. Front Mol Neurosci, 2018, 11: 408.
|
| [2] |
Waker CA, Lober RM. Brain tumors of glial origin[J]. Adv Exp Med Biol, 2019, 1190: 281-297.
|
| [3] |
Janin M, Ortiz-Barahona V, de Moura MC, et al. Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program[J]. Acta Neuropathol, 2019, 138(6): 1053-1074.
|
| [5] |
Ciechomska IA, Jayaprakash C, Maleszewska M, et al. Histone modifying enzymes and chromatin modifiers in glioma pathobiology and therapy responses[J]. Adv Exp Med Biol, 2020, 1202: 259-279.
|
| [6] |
Morgan AE, Davies TJ, Mc Auley MT. The role of DNA methylation in ageing and cancer[J]. Proc Nutr Soc, 2018, 77(4): 412-422.
|
| [7] |
Meng H, Cao Y, Qin J, et al. DNA methylation, its mediators and genome integrity[J]. Int J Biol Sci, 2015, 11(5): 604-617.
|
| [8] |
Liu Y, Lang F, Chou FJ, et al. Isocitrate dehydrogenase mutations in glioma: genetics, biochemistry, and clinical indications[J]. Biomedicines, 2020, 8(9): 294.
|
| [9] |
Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma[J]. Cancer Cell, 2010, 17(5): 510-522.
|
| [10] |
Su R, Dong L, Li C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling[J]. Cell, 2018, 172(1-2): 90-105.e23.
|
| [11] |
王振. MGMT基因启动子甲基化及IDH1基因突变在胶质瘤中的临床意义及预后价值[D]. 大连: 大连医科大学, 2017.
|
| [12] |
Watanabe T, Huang H, Nakamura M, et al. Methylation of the p73 gene in gliomas[J]. Acta Neuropathol, 2002, 104(4): 357-362.
|
| [13] |
Jiang Z, Li X, Hu J, et al. Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma[J]. Neurosci Res, 2006, 56(4): 450-458.
|
| [14] |
姜政，周伟，李新钢, 等. 人脑胶质瘤中EMP3和PCDH-γ-A11基因的甲基化调控[J]. 中华外科杂志, 2010, 48(4): 300-304.
|
| [15] |
Weller M. Assessing the MGMT status in glioblastoma: one step forward, two steps back?[J]. Neuro Oncol, 2013, 15(3): 253-254.
|
| [16] |
Hua XM, Wang J, Qian DM, et al. DNA methylation level of promoter region of activating transcription factor 5 in glioma[J]. J Zhejiang Univ Sci B, 2015, 16(9): 757-762.
|
| [17] |
Duncan CG, Barwick BG, Jin G, et al. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation[J]. Genome Res, 2012, 22(12): 2339-2355.
|
| [18] |
Bai Y, Zhang QG, Wang XH. Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome[J]. Eur J Med Res, 2014, 19(1): 66.
|
| [19] |
Wang S, Shi X, Wei S, et al. Krüppel-like factor 4 (KLF4) induces mitochondrial fusion and increases spare respiratory capacity of human glioblastoma cells[J]. J Biol Chem, 2018, 293(17): 6544-6555.
|
| [20] |
Zhou D, Wan Y, Xie D, et al. DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells[J]. Exp Mol Med, 2015, 47(9): e182.
|
| [21] |
Shan ZN, Tian R, Zhang M, et al. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3[J]. Oncotarget, 2016, 7(48): 78813-78826.
|
| [22] |
Fukushima T, Kawaguchi M, Yamamoto K, et al. Aberrant methylation and silencing of the SPINT2 gene in high-grade gliomas[J]. Cancer Sci, 2018, 109(9): 2970-2979.
|
| [23] |
Cui H, Mu Y, Yu L, et al. Methylation of the miR-126 gene associated with glioma progression[J]. Fam Cancer, 2016, 15(2): 317-324.
|
| [24] |
Hong C, Moorefield KS, Jun P, et al. Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth[J]. Proc Natl Acad Sci USA, 2007, 104(26): 10974-10979.
|
| [25] |
Alaminos M, Dávalos V, Ropero S, et al. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma[J]. Cancer Res, 2005, 65(7): 2565-2571.
|
| [26] |
Lindemann C, Hackmann O, Delic S, et al. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation[J]. Acta Neuropathol, 2011, 122(2): 241-251.
|
| [27] |
Kurscheid S, Bady P, Sciuscio D, et al. Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma[J]. Genome Biol, 2015, 16(1): 16.
|
| [28] |
Gömöri E, Pál J, Kovács B, et al. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas[J]. Diagn Pathol, 2012, 7: 8.
|
| [29] |
Qi C, Lei L, Hu J, et al. Thrombospondin-1 is a prognostic biomarker and is correlated with tumor immune microenvironment in glioblastoma[J]. Oncol Lett, 2021, 21(1): 22.
|
| [30] |
Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer[J]. Dis Markers, 2007, 23(1-2): 73-87.
|
| [31] |
Liu L, Chen K, Wu J, et al. Downregulation of miR-452 promotes stem-like traits and tumorigenicity of gliomas[J]. Clin Cancer Res, 2013, 19(13): 3429-3438.
|
| [32] |
Fan K, Wang X, Zhang J, et al. Hypomethylation of CNTFRα is associated with proliferation and poor prognosis in lower grade gliomas[J]. Sci Rep, 2017, 7(1): 7079.
|
| [33] |
Chen J, Gong M, Lu S, et al. Detection of serum Alu element hypomethylation for the diagnosis and prognosis of glioma[J]. J Mol Neurosci, 2013, 50(2): 368-375.
|
| [34] |
Steponaitis G, Kazlauskas A, Vaitkienė P, et al. Oncosuppressive role of RUNX3 in human astrocytomas[J]. J Oncol, 2019, 2019: 1232434.
|
| [35] |
Dong X, Deng Q, Nie X, et al. Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma[J]. Exp Mol Pathol, 2015, 98(2): 192-199.
|
| [36] |
Chu SH, Feng DF, Ma YB, et al. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma[J]. J Transl Med, 2011, 9: 156.
|
| [37] |
Kolodziej MA, Weischer C, Reinges MH, et al. NDRG2 and NDRG4 expression is altered in glioblastoma and influences survival in patients with MGMT-methylated tumors[J]. Anticancer Res, 2016, 36(3): 887-897.
|
| [38] |
Majchrzak-Celińska A, Sńocińska M, Barciszewska AM, et al. Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival[J]. J Appl Genet, 2016, 57(2): 189-197.
|
| [39] |
Delpu Y, Cordelier P, Cho WC, et al. DNA methylation and cancer diagnosis[J]. Int J Mol Sci, 2013, 14(7): 15029-15058.
|
| [40] |
Mendez FM, Núñez FJ, Garcia-Fabiani MB, et al. Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease[J]. Neuro Oncol, 2020, 22(2): 195-206.
|
| [41] |
El-Hashash AHK. Histone H3K27M mutation in brain tumors[J]. Adv Exp Med Biol, 2021, 1283: 43-52.
|
| [42] |
Ganguly D, Sims M, Cai C, et al. Chromatin remodeling factor BRG1 regulates stemness and chemosensitivity of glioma initiating cells[J]. Stem Cells, 2018, 36(12): 1804-1815.
|
| [43] |
Masliah-Planchon J, Bièche I, Guinebretière JM, et al. SWI/SNF chromatin remodeling and human malignancies[J]. Annu Rev Pathol, 2015, 10: 145-171.
|
| [44] |
Yu L, Xu J, Liu J, et al. The novel chromatin architectural regulator SND1 promotes glioma proliferation and invasion and predicts the prognosis of patients[J]. Neuro Oncol, 2019, 21(6): 742-754.
|
| [45] |
Dong Z, Cui H. The emerging roles of RNA modifications in glioblastoma[J]. Cancers (Basel), 2020, 12(3): 736.
|
| [46] |
Zhang Y, Geng X, Li Q, et al. m6A modification in RNA: biogenesis, functions and roles in gliomas[J]. J Exp Clin Cancer Res, 2020, 39(1): 192.
|
| [47] |
Peng Z, Liu C, Wu M. New insights into long noncoding RNAs and their roles in glioma[J]. Mol Cancer, 2018, 17(1): 61.
|
| [48] |
Zhou K, Zhang C, Yao H, et al. Knockdown of long non-coding RNA NEAT1 inhibits glioma cell migration and invasion via modulation of SOX2 targeted by miR-132[J]. Mol Cancer, 2018, 17(1): 105.
|
| [49] |
Xiao Y, Zhu Z, Li J, et al. Expression and prognostic value of long non-coding RNA H19 in glioma via integrated bioinformatics analyses[J]. Aging (Albany NY), 2020, 12(4): 3407-3430.
|
| [50] |
Zhang D, Zhou H, Liu J, et al. Long noncoding RNA ASB16-AS1 promotes proliferation, migration, and invasion in glioma cells[J]. Biomed Res Int, 2019, 2019: 5437531.
|
| [51] |
Chai C, Song LJ, Han SY, et al. MicroRNA-21 promotes glioma cell proliferation and inhibits senescence and apoptosis by targeting SPRY1 via the PTEN/PI3K/AKT signaling pathway[J]. CNS Neurosci Ther, 2018, 24(5): 369-380.
|
| [52] |
Mohammad F, Weissmann S, Leblanc B, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas[J]. Nat Med, 2017, 23(4): 483-492.
|